Schering-Plough Corp said its
Elocon topical steroid for inflammatory skin disorders has been
approved for marketing by the U.S. Food and Drug Administration
in cream and ointment forms for once-daily applications.
    The company said overseas health agency registrations for
Elocon are scheduled to be submitted in a number of major
markets this year and in other areas in 1988.
 Reuter
&#3;